Labgenomics Co

Labgenomics Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Labgenomics Co (084650.KQ) as of Nov 14, 2026 is -4.29. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -4.37 — a change of -1.70% (higher).

EV/FCF

-4.29

YoY

-1.70%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Labgenomics Co is 2025 -4.29 . EV/FCF (Enterprise Value to Free Cash Flow) of Labgenomics Co was 2024 -4.37 . It decreases by -1.70% higher compared to the previous year.

The Labgenomics Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-84.63 KRW
Jan 1, 2019
46.02 KRW
Jan 1, 2020
1.67 KRW
Jan 1, 2021
0.59 KRW
Jan 1, 2022
0.27 KRW
Jan 1, 2023
-10.27 KRW
Jan 1, 2024
-4.37 KRW
Jan 1, 2025
-4.29 KRW
The Labgenomics Co EV/FCF history
YEAREV/FCFYoY
-4.29-1.70%
-4.37-57.47%
-10.27-3,946.93%
0.27-54.95%
0.59-64.49%
1.67-96.37%
46.02-154.38%
-84.63+249.91%
-24.19-70.38%
-81.66+43.79%
-56.79-187.71%
64.75—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of Labgenomics Co is -4.29 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Labgenomics Co changed from -4.37 to -4.29, representing a -1.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Labgenomics Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Labgenomics Co

All Key Metrics — Labgenomics Co